Morgan Stanley analyst Judah Frommer initiated coverage of Trevi Therapeutics (TRVI) with an Overweight rating and $18 price target The company is developing Haduvio, an extended-release formulation of nalbuphine for chronic cough, where existing therapies provide limited relief, the analyst tells investors in a research note. The firm sees a multi-billion dollar opportunity for Haduvio. The drug is “de-risked and differentiated” and should address a significant treatment gap, contends Morgan Stanley.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics CFO Resignation Announced
- Trevi Therapeutics: Optimism Amid Earnings Call Insights
- Promising Developments and Strategic Expansion Bolster Trevi Therapeutics’ Growth Potential
- Trevi Therapeutics price target lowered to $27 from $29 at Raymond James
- Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics